Chadwick Mills


As a single global partnership, Cooley brings to the table a cutting-edge, firmwide skill set to address the most significant legal matters affecting our clients. We work closely with our clients to understand each client’s business and strategic objectives, always striving to provide timely, comprehensive and pragmatic legal advice necessary to help our clients achieve their objectives. At the end of the day, I believe that it’s our commitment to client service, as well as our attitude of partnership with our clients, that really sets us apart.

Chadwick L. Mills is co-chair of Cooley's public companies practice, and specializes in corporate and securities law, and regularly acts as outside corporate counsel to public life sciences companies. Chad provides ongoing compliance and strategic advice to biotechnology, pharmaceutical and device companies and their boards of directors on a wide range of securities, corporate and investor outreach matters, including financial reporting and disclosure issues, shareholder engagement and activism, securities offerings and corporate governance matters, in each case based on his extensive experience in the public life sciences space.

Download full bio 


  • Horizon Therapeutics to Be Acquired by Amgen for Approximately $28 Billion 

  • Lyell Immunopharma – $425 Million IPO 

  • Kronos Bio – $288 million IPO 

  • BioMarin – $720 Million Follow-On Offering 

  • Cooley Advised Jazz Pharmaceuticals on Rule 144A Offering of $575 Million of Exchangeable Senior Notes 

  • View all


  • University of California Hastings College of the Law
    JD, cum laude, Order of the Coif, 1999

  • University of Wisconsin, Madison
    BS, Political Science
    with distinction, 1996

Admissions & Credentials